KRYS vs. LLY
Compare and contrast key facts about Krystal Biotech, Inc. (KRYS) and Eli Lilly and Company (LLY).
Performance
KRYS vs. LLY - Performance Comparison
Loading graphics...
KRYS vs. LLY - Yearly Performance Comparison
| 2026 (YTD) | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | |
|---|---|---|---|---|---|---|---|---|---|---|
KRYS Krystal Biotech, Inc. | 5.02% | 57.37% | 26.28% | 56.60% | 13.25% | 16.58% | 8.34% | 166.51% | 97.53% | -1.13% |
LLY Eli Lilly and Company | -11.03% | 40.25% | 33.30% | 60.91% | 34.26% | 66.08% | 31.04% | 16.14% | 40.45% | 3.63% |
Fundamentals
KRYS:
$7.75B
LLY:
$857.16B
KRYS:
$6.86
LLY:
$22.96
KRYS:
37.72
LLY:
41.57
KRYS:
0.09
LLY:
0.84
KRYS:
19.86
LLY:
13.16
KRYS:
6.36
LLY:
32.30
KRYS:
$389.13M
LLY:
$65.18B
KRYS:
$0.00
LLY:
$54.62B
KRYS:
$161.30M
LLY:
$27.94B
Returns By Period
In the year-to-date period, KRYS achieves a 5.02% return, which is significantly higher than LLY's -11.03% return.
KRYS
- 1D
- 0.23%
- 1M
- 0.04%
- YTD
- 5.02%
- 6M
- 44.15%
- 1Y
- 48.30%
- 3Y*
- 47.88%
- 5Y*
- 27.54%
- 10Y*
- —
LLY
- 1D
- 3.78%
- 1M
- -6.23%
- YTD
- -11.03%
- 6M
- 16.00%
- 1Y
- 19.42%
- 3Y*
- 41.64%
- 5Y*
- 40.20%
- 10Y*
- 31.41%
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Return for Risk
KRYS vs. LLY — Risk / Return Rank
KRYS
LLY
KRYS vs. LLY - Risk-Adjusted Trends Comparison
This table presents a comparison of risk-adjusted performance metrics for Krystal Biotech, Inc. (KRYS) and Eli Lilly and Company (LLY). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
| KRYS | LLY | Difference | |
|---|---|---|---|
Sharpe ratioReturn per unit of total volatility | 1.14 | 0.46 | +0.68 |
Sortino ratioReturn per unit of downside risk | 1.61 | 0.90 | +0.71 |
Omega ratioGain probability vs. loss probability | 1.22 | 1.13 | +0.09 |
Calmar ratioReturn relative to maximum drawdown | 1.37 | 0.54 | +0.83 |
Martin ratioReturn relative to average drawdown | 2.98 | 1.33 | +1.66 |
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month. | |||
Loading graphics...
Sharpe Ratios by Period
| KRYS | LLY | Difference | |
|---|---|---|---|
Sharpe Ratio (1Y)Calculated over the trailing 1-year period | 1.14 | 0.46 | +0.68 |
Sharpe Ratio (5Y)Calculated over the trailing 5-year period | 0.36 | 1.26 | -0.89 |
Sharpe Ratio (10Y)Calculated over the trailing 10-year period | — | 1.06 | — |
Sharpe Ratio (All Time)Calculated using the full available price history | 0.61 | 0.57 | +0.04 |
Correlation
The correlation between KRYS and LLY is 0.20, which is considered to be low. This implies their price changes are not closely related. A low correlation is generally favorable for portfolio diversification, as it helps to reduce overall risk by spreading it across multiple assets with different performance patterns.
Dividends
KRYS vs. LLY - Dividend Comparison
KRYS has not paid dividends to shareholders, while LLY's dividend yield for the trailing twelve months is around 0.65%.
| TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
KRYS Krystal Biotech, Inc. | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
LLY Eli Lilly and Company | 0.65% | 0.56% | 0.67% | 0.78% | 1.07% | 1.23% | 1.75% | 1.96% | 1.94% | 2.46% | 2.77% | 2.37% |
Drawdowns
KRYS vs. LLY - Drawdown Comparison
The maximum KRYS drawdown since its inception was -53.42%, smaller than the maximum LLY drawdown of -68.24%. Use the drawdown chart below to compare losses from any high point for KRYS and LLY.
Loading graphics...
Drawdown Indicators
| KRYS | LLY | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -53.42% | -68.24% | +14.82% |
Max Drawdown (1Y)Largest decline over 1 year | -31.85% | -30.26% | -1.59% |
Max Drawdown (5Y)Largest decline over 5 years | -51.34% | -34.48% | -16.86% |
Max Drawdown (10Y)Largest decline over 10 years | — | -34.48% | — |
Current DrawdownCurrent decline from peak | -11.31% | -13.86% | +2.55% |
Average DrawdownAverage peak-to-trough decline | -16.43% | -19.25% | +2.82% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 14.61% | 12.39% | +2.22% |
Volatility
KRYS vs. LLY - Volatility Comparison
Krystal Biotech, Inc. (KRYS) and Eli Lilly and Company (LLY) have volatilities of 9.78% and 9.94%, respectively, indicating that both stocks experience similar levels of price fluctuations. This suggests that the risk associated with both stocks, as measured by volatility, is nearly the same. The chart below showcases a comparison of their rolling one-month volatility.
Loading graphics...
Volatility by Period
| KRYS | LLY | Difference | |
|---|---|---|---|
Volatility (1M)Calculated over the trailing 1-month period | 9.78% | 9.94% | -0.16% |
Volatility (6M)Calculated over the trailing 6-month period | 25.71% | 26.02% | -0.31% |
Volatility (1Y)Calculated over the trailing 1-year period | 42.66% | 42.60% | +0.06% |
Volatility (5Y)Calculated over the trailing 5-year period, annualized | 76.66% | 32.17% | +44.49% |
Volatility (10Y)Calculated over the trailing 10-year period, annualized | 74.80% | 29.82% | +44.98% |
Financials
KRYS vs. LLY - Financials Comparison
This section allows you to compare key financial metrics between Krystal Biotech, Inc. and Eli Lilly and Company. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.
Total Revenue: Total amount of money received from sales and other business activities